双环醇联合血滞通胶囊对非酒精性脂肪性肝病的疗效研究OA
Efficacy of bicyclol combined with Xuezhitong capsules in the treat-ment of non-alcoholic fatty liver disease
目的:系统评价双环醇片与血滞通胶囊联用方案对非酒精性脂肪肝(NAFLD)患者的综合治疗效果及安全性特征.方法:研究设计采用前瞻性随机对照试验,将 160例 NAFLD 患者以1:1比例分配至两组:对照组 80例接受双环醇片单一药物治疗,治疗组80例则采用双环醇片联合血滞通胶囊的复合治疗方案,全程治疗周期为12周.研究重点比较两组患者治疗前后肝功能关键指标,包括丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、γ-谷氨酰转肽酶(GGT)、血脂谱参数[总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、肝纤维化进展指标、炎症介质水平变化以及不良反应事件发生率.结果:经过 12周系统治疗后,两组患者的肝功能指标及血脂参数均呈现显著改善趋势(P<0.05).值得注意的是,治疗组在 ALT 水平下降41.8%(对照组为 26.4%)、AST 降低 33.9%(对照组为 21.8%)、TC 减少 14.4%(对照组为9.6%)、TG 降幅达 25.2%(对照组为 14.3%)等关键指标的改善幅度上,显著优于对照组(P<0.05).此外,治疗组的复合终点应答率为88.8%,明显优于对照组(66.2%)(P=0.001).药物安全性分析显示,两组间不良反应发生率差异无统计学意义(6.9%vs.10.6%,P=0.323).结论:双环醇片与血滞通胶囊的联合治疗方案在NAFLD 治疗中展现出临床疗效优势,其治疗效果显著优于单药治疗.这一治疗策略为 NAFLD 的临床管理提供了良好的治疗选择.
AIM:To systematically evaluate the comprehensive therapeutic efficacy and safety pro-file of the combination therapy of bicyclol tablets and Xuezhitong capsules in patients with non-alco-holic fatty liver disease(NAFLD).The research de-sign employed a prospective randomized con-trolled trial,allocating 160 NAFLD patients in a 1:1 ratio to two groups:the control group(n=80)re-ceived bicyclol tablets monotherapy,while the ex-perimental group(n=80)underwent a combination therapy of bicyclol tablets and Xuezhitong capsules,with a total treatment duration of 12 weeks.The study focused on comparing key liver function indi-cators,including alanine aminotransferase(ALT),as-partate aminotransferase(AST),γ-glutamyl transpeptidase(GGT),lipid profile parameters,in-cluding total cholesterol(TC),triglycerides(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),liver fibro-sis progression markers,inflammatory mediator lev-els,and adverse event incidence rates between the two groups before and after treatment.RESULTS:After 12 weeks of systematic treatment,both groups demonstrated significant improvements in liver function indicators and lipid profile parame-ters(P<0.05).Notably,the experimental group showed superior improvements in key indicators compared to the control group:ALT levels de-creased by 41.8%(vs.26.4%in the control group),AST reduced by 33.9%(vs.21.8%),TC decreased by 14.4%(vs.9.6%),and TG showed a reduction of 25.2%(vs.14.3%)(P<0.05).Furthermore,the com-posite endpoint response rate in the experimental group was 88.8%,significantly higher than the con-trol group's 66.2%(P=0.001).Safety analysis re-vealed no statistically significant difference in ad-verse event incidence between the two groups(6.9%vs.10.6%,P=0.323).CONCLUSION:The com-bination therapy of bicyclol tablets and Xuezhitong capsules demonstrates superior clinical efficacy in NAFLD treatment.This innovative therapeutic strat-egy provides an optimal treatment option for the clinical management of NAFLD.
金怡珊;江凤翔;谭姣容;朱明华
同济大学附属普陀人民医院 内分泌科,上海 200060同济大学附属普陀人民医院 消化内科,上海 200060同济大学附属普陀人民医院 内分泌科,上海 200060上海市公共卫生临床中心 检验医学科,上海 200083
医药卫生
非酒精性脂肪肝双环醇片血滞通胶囊肝功能血脂
non-alcoholic fatty liver diseasebicy-clolXuezhitong capsuleliver functionlipids
《中国临床药理学与治疗学》 2026 (4)
486-492,7
上海市普陀区卫生健康系统科技创新重点项目(ptkwws202502)
评论